Trevena Inc (NASDAQ:TRVN) Expected to Announce Earnings of -$0.08 Per Share

Share on StockTwits

Equities analysts expect Trevena Inc (NASDAQ:TRVN) to report earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks. Zero analysts have provided estimates for Trevena’s earnings. Trevena posted earnings of ($0.10) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 20%. The business is expected to report its next earnings report on Wednesday, March 11th.

According to Zacks, analysts expect that Trevena will report full-year earnings of ($0.28) per share for the current financial year. For the next fiscal year, analysts expect that the business will report earnings of ($0.34) per share. Zacks’ EPS calculations are an average based on a survey of research firms that follow Trevena.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01).

Several analysts recently weighed in on TRVN shares. ValuEngine lowered Trevena from a “hold” rating to a “sell” rating in a report on Wednesday, November 6th. Zacks Investment Research lowered Trevena from a “hold” rating to a “sell” rating in a research note on Saturday, November 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.50 target price on shares of Trevena in a research note on Tuesday, November 5th.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Trevena by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,915,315 shares of the biopharmaceutical company’s stock worth $4,032,000 after buying an additional 403,060 shares in the last quarter. BlackRock Inc. raised its stake in shares of Trevena by 1.9% in the second quarter. BlackRock Inc. now owns 2,647,830 shares of the biopharmaceutical company’s stock worth $2,727,000 after purchasing an additional 49,900 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Trevena by 50.2% in the second quarter. Renaissance Technologies LLC now owns 1,928,850 shares of the biopharmaceutical company’s stock worth $1,987,000 after purchasing an additional 644,812 shares during the last quarter. Morgan Stanley raised its stake in shares of Trevena by 2,651.1% in the second quarter. Morgan Stanley now owns 530,436 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 511,155 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Trevena in the second quarter worth about $264,000. 23.72% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:TRVN traded down $0.04 during midday trading on Monday, hitting $0.63. 31,886 shares of the company traded hands, compared to its average volume of 1,587,975. The firm’s fifty day moving average is $0.89 and its 200-day moving average is $1.01. Trevena has a 12-month low of $0.38 and a 12-month high of $2.00. The firm has a market capitalization of $66.67 million, a P/E ratio of -1.52 and a beta of 2.63. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of 0.23.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Further Reading: Understanding Options Trading

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Berry Petroleum  Given “Hold” Rating at Wells Fargo & Co
Berry Petroleum Given “Hold” Rating at Wells Fargo & Co
John Hancock Hedged Equity and Income Declares Quarterly Dividend of $0.38
John Hancock Hedged Equity and Income Declares Quarterly Dividend of $0.38
Pimco Corporate & Income Strategy Fund  Announces Monthly Dividend of $0.11
Pimco Corporate & Income Strategy Fund Announces Monthly Dividend of $0.11
Cronos Group Inc  Given Consensus Rating of “Hold” by Brokerages
Cronos Group Inc Given Consensus Rating of “Hold” by Brokerages
Bicycle Therapeutics Limited  Given Average Recommendation of “Buy” by Analysts
Bicycle Therapeutics Limited Given Average Recommendation of “Buy” by Analysts
The Currency Analytics  Achieves Market Capitalization of $46,977.00
The Currency Analytics Achieves Market Capitalization of $46,977.00


© 2006-2019 Ticker Report